A Randomized, Double-Blind, Placebo Controlled, Phase I Study to Assess, Safety, Tolerability, Pharmacokinetics of HS-10383 Administered Orally in China Healthy Adult Subjects
Latest Information Update: 06 Jun 2024
Price :
$35 *
At a glance
- Drugs HS 10383 (Primary)
- Indications Cough
- Focus Adverse reactions; First in man
- Sponsors Jiangsu Hansoh Pharmaceutical
- 28 Jun 2022 New trial record